(secondQuint)TEW-7197 in Combination w/ Pomalidomide in Relapsed or Relapsed and Refractory Multiple Myeloma.

 Primary Objective - To determine the maximum tolerated dose (MTD) or maximum tested dose level of TEW-7197 given in combination with pomalidomide (POM) for the treatment of relapsed or relapsed or refractory multiple myeloma (RRMM) - To characterize the safety and tolerability profile of TEW-7197 in combination with POM at the MTD Secondary Objectives - To assess response and clinical benefit response rates according to international uniform response criteria - Progression-free survival (PFS) and PFS at 6 months (PFS-6) Study Design This study is a Phase I, open label trial of TEW-7197 in combination with standard doses of POM.

 The study will be conducted as a modified Fibonacci 3 + 3 dose escalation design to determine the MTD of TEW-7197 in combination with standard doses of POM.

 Patients will receive combination TEW-7197 /POM.

.

 TEW-7197 in Combination w/ Pomalidomide in Relapsed or Relapsed and Refractory Multiple Myeloma@highlight

The purpose of this study is to see if the study drug, called TEW-7197, is safe and determine what the best dose is to treat future patients when given in combination with pomalidomide (POM).

 The study will also look to see if it has any effect on multiple myeloma, when given in combination with POM.

